Thermo Fisher Scientific Revenue Recognized from Contract Liabilities decreased by 5.1% to $1.29B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 5.1%, from $1.36B to $1.29B. This decline may warrant attention — for this metric, higher values are generally preferred.
Consistent recognition of deferred revenue indicates a healthy pipeline of service delivery and stable business operations.
This metric tracks the portion of revenue recognized during the period that was previously recorded as deferred revenue...
Commonly analyzed for SaaS and subscription-based business models.
isrg_contract_liability_revenue_recognized| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $370.00M | $170.00M | $1.28B | $710.00M | $340.00M | $1.30B | $680.00M | $350.00M | $1.32B | $670.00M | $360.00M | $1.36B | $1.29B |
| QoQ Change | — | -54.1% | +652.9% | -44.5% | -52.1% | +282.4% | -47.7% | -48.5% | +277.1% | -49.2% | -46.3% | +277.8% | -5.1% |
| YoY Change | — | — | — | +91.9% | +100.0% | +1.6% | -4.2% | +2.9% | +1.5% | -1.5% | +2.9% | +3.0% | -5.1% |